Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00285857 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00285857: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT00285857 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00285857, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease abnormal breast duct cytology in women with a high inherited breast cancer risk.
Interventions
- DRUG Lovastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-11 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00285857
The ClinicalTrials.gov registry entry for NCT00285857 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lovastatin is the first listed.
NCT00285857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00285857 about?
NCT00285857 is a clinical study titled "Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention". The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease abnormal breast duct cytology in women with a high inherited breast cancer risk.
What is the current status of trial NCT00285857?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-11. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00285857?
The interventions under investigation include: Lovastatin (DRUG).
Who is sponsoring clinical trial NCT00285857?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.